Novo Nordisk Net Worth
Novo Nordisk Net Worth Breakdown | NVO |
Novo Nordisk Net Worth Analysis
Novo Nordisk's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Novo Nordisk's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Novo Nordisk's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Novo Nordisk's net worth analysis. One common approach is to calculate Novo Nordisk's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Novo Nordisk's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Novo Nordisk's net worth. This approach calculates the present value of Novo Nordisk's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Novo Nordisk's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Novo Nordisk's net worth. This involves comparing Novo Nordisk's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Novo Nordisk's net worth relative to its peers.
Enterprise Value |
|
To determine if Novo Nordisk is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Novo Nordisk's net worth research are outlined below:
| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has 102.79 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Novo to invest in growth at high rates of return. | |
| Latest headline from gurufocus.com: NVO INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Novo Nordisk AS ... |
Novo Nordisk uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Novo Nordisk AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Novo Nordisk's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Novo Nordisk Target Price Consensus
Novo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Novo Nordisk's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Buy |
Most Novo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Novo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Novo Nordisk AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNovo Nordisk Target Price Projection
Novo Nordisk's current and average target prices are 79.00 and 114.68, respectively. The current price of Novo Nordisk is the price at which Novo Nordisk AS is currently trading. On the other hand, Novo Nordisk's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Novo Nordisk Market Quote on 20th of March 2025
Target Price
Analyst Consensus On Novo Nordisk Target Price
Know Novo Nordisk's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novo Nordisk is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novo Nordisk AS backward and forwards among themselves. Novo Nordisk's institutional investor refers to the entity that pools money to purchase Novo Nordisk's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-12-31 | 1.8 M |
Follow Novo Nordisk's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 357.03 B.Market Cap |
|
Project Novo Nordisk's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.28 | 0.15 | |
| Return On Capital Employed | 0.52 | 0.29 | |
| Return On Assets | 0.22 | 0.14 | |
| Return On Equity | 0.70 | 0.74 |
When accessing Novo Nordisk's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Novo Nordisk's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Novo Nordisk's profitability and make more informed investment decisions.
Evaluate Novo Nordisk's management efficiency
Novo Nordisk AS has Return on Asset of 0.2241 % which means that on every $100 spent on assets, it made $0.2241 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8078 %, implying that it generated $0.8078 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Equity is likely to grow to 0.74, while Return On Tangible Assets are likely to drop 0.15. At this time, Novo Nordisk's Other Assets are very stable compared to the past year. As of the 20th of March 2025, Net Tangible Assets is likely to grow to about 37 B, while Return On Tangible Assets are likely to drop 0.15.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.22 | 33.83 | |
| Tangible Book Value Per Share | 7.27 | 4.76 | |
| Enterprise Value Over EBITDA | 20.87 | 21.92 | |
| Price Book Value Ratio | 19.38 | 20.34 | |
| Enterprise Value Multiple | 20.87 | 21.92 | |
| Price Fair Value | 19.38 | 20.34 | |
| Enterprise Value | 729.2 B | 765.7 B |
The leadership approach at Novo Nordisk's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 8.5972 | Revenue | Quarterly Revenue Growth 0.301 | Revenue Per Share | Return On Equity |
Novo Nordisk Corporate Filings
6K | 10th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
Novo Nordisk Earnings Estimation Breakdown
The calculation of Novo Nordisk's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Novo Nordisk is estimated to be 6.2605 with the future projection ranging from a low of 6.06 to a high of 6.461. Please be aware that this consensus of annual earnings estimates for Novo Nordisk AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
6.06 Lowest | Expected EPS | 6.46 Highest |
Novo Nordisk Earnings Projection Consensus
Suppose the current estimates of Novo Nordisk's value are higher than the current market price of the Novo Nordisk stock. In this case, investors may conclude that Novo Nordisk is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Novo Nordisk's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 11 | 94.83% | 6.34 | 6.2605 | 3.3 |
Novo Nordisk Earnings History
Earnings estimate consensus by Novo Nordisk AS analysts from Wall Street is used by the market to judge Novo Nordisk's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Novo Nordisk's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Novo Nordisk Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novo Nordisk's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Novo Nordisk Earnings per Share Projection vs Actual
Actual Earning per Share of Novo Nordisk refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Novo Nordisk AS predict the company's earnings will be in the future. The higher the earnings per share of Novo Nordisk, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Novo Nordisk Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Novo Nordisk, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Novo Nordisk should always be considered in relation to other companies to make a more educated investment decision.Novo Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Novo Nordisk's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-05 | 2024-12-31 | 6.115 | 6.34 | 0.225 | 3 | ||
2024-11-06 | 2024-09-30 | 0.88 | 0.9 | 0.02 | 2 | ||
2024-08-07 | 2024-06-30 | 0.7366 | 0.66 | -0.0766 | 10 | ||
2024-05-02 | 2024-03-31 | 0.77 | 0.83 | 0.06 | 7 | ||
2024-01-31 | 2023-12-31 | 0.66 | 0.71 | 0.05 | 7 | ||
2023-11-02 | 2023-09-30 | 0.69 | 0.73 | 0.04 | 5 | ||
2023-08-10 | 2023-06-30 | 0.63 | 0.67 | 0.04 | 6 | ||
2023-05-04 | 2023-03-31 | 0.61 | 0.63 | 0.02 | 3 | ||
2023-02-01 | 2022-12-31 | 0.4329 | 0.41 | -0.0229 | 5 | ||
2022-11-02 | 2022-09-30 | 0.4189 | 0.43 | 0.0111 | 2 | ||
2022-08-04 | 2022-06-30 | 0.4099 | 0.42 | 0.0101 | 2 | ||
2022-04-28 | 2022-03-31 | 0.4233 | 0.47 | 0.0467 | 11 | ||
2022-02-02 | 2021-12-31 | 0.3566 | 0.36 | 0.0034 | 0 | ||
2021-11-03 | 2021-09-30 | 0.3884 | 0.42 | 0.0316 | 8 | ||
2021-08-04 | 2021-06-30 | 0.3912 | 0.419 | 0.0278 | 7 | ||
2021-05-05 | 2021-03-31 | 0.4035 | 0.44 | 0.0365 | 9 | ||
2021-02-03 | 2020-12-31 | 0.3243 | 0.3239 | -4.0E-4 | 0 | ||
2020-11-03 | 2020-09-30 | 0.3151 | 0.345 | 0.0299 | 9 | ||
2020-08-07 | 2020-06-30 | 0.36 | 0.3593 | -7.0E-4 | 0 | ||
2020-05-05 | 2020-03-31 | 0.345 | 0.3655 | 0.0205 | 5 | ||
2020-02-05 | 2019-12-31 | 0.28 | 0.2724 | -0.0076 | 2 | ||
2019-11-01 | 2019-09-30 | 0.305 | 0.3207 | 0.0157 | 5 | ||
2019-08-09 | 2019-06-30 | 0.3 | 0.3025 | 0.0025 | 0 | ||
2019-05-03 | 2019-03-31 | 0.305 | 0.3267 | 0.0217 | 7 | ||
2019-02-01 | 2018-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2018-11-01 | 2018-09-30 | 0.285 | 0.2857 | 7.0E-4 | 0 | ||
2018-08-10 | 2018-06-30 | 0.325 | 0.3267 | 0.0017 | 0 | ||
2018-05-02 | 2018-03-31 | 0.335 | 0.355 | 0.02 | 5 | ||
2018-02-01 | 2017-12-31 | 0.29 | 0.2815 | -0.0085 | 2 | ||
2017-10-27 | 2017-09-30 | 0.305 | 0.315 | 0.01 | 3 | ||
2017-08-09 | 2017-06-30 | 0.3 | 0.3165 | 0.0165 | 5 | ||
2017-05-03 | 2017-03-31 | 0.265 | 0.2979 | 0.0329 | 12 | ||
2017-02-06 | 2016-12-31 | 0.25 | 0.2468 | -0.0032 | 1 | ||
2016-10-28 | 2016-09-30 | 0.28 | 0.2844 | 0.0044 | 1 | ||
2016-08-05 | 2016-06-30 | 1.87 | 0.295 | -1.575 | 84 | ||
2016-04-29 | 2016-03-31 | 1.815 | 0.275 | -1.54 | 84 | ||
2016-02-03 | 2015-12-31 | 1.61 | 0.24 | -1.37 | 85 | ||
2015-10-29 | 2015-09-30 | 1.585 | 0.245 | -1.34 | 84 | ||
2014-05-01 | 2014-03-31 | 0.44 | 0.45 | 0.01 | 2 | ||
2012-04-30 | 2012-03-31 | 0.3 | 0.29 | -0.01 | 3 | ||
2012-02-02 | 2011-12-31 | 0.26 | 0.3 | 0.04 | 15 | ||
2011-10-27 | 2011-09-30 | 0.26 | 0.28 | 0.02 | 7 | ||
2011-08-04 | 2011-06-30 | 0.29 | 0.28 | -0.01 | 3 | ||
2011-02-02 | 2010-12-31 | 0.27 | 0.25 | -0.02 | 7 | ||
2010-10-27 | 2010-09-30 | 0.22 | 0.21 | -0.01 | 4 | ||
2006-10-27 | 2006-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2006-08-02 | 2006-06-30 | 0.09 | 0.09 | 0.0 | 0 | ||
1995-03-08 | 1994-12-31 | 0.02 | 0.02 | 0.0 | 0 | ||
1994-12-22 | 1994-09-30 | 0.02 | 0.02 | 0.0 | 0 | ||
1993-05-15 | 1993-03-31 | 0.01 | 0.01 | 0.0 | 0 |
Novo Nordisk Corporate Directors
| Kasim Kutay | Director | Profile | |
| Sylvie Gregoire | Independent Director | Profile | |
| Mette Jensen | Director, Employee Representative | Profile | |
| Thomas Rantzau | Director, Employee Representative | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.292 | Dividend Share 11.4 | Earnings Share 3.3 | Revenue Per Share | Quarterly Revenue Growth 0.301 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.